KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) EBITDA (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed EBITDA for 12 consecutive years, with -$3.4 million as the latest value for Q4 2024.

  • On a quarterly basis, EBITDA fell 108.87% to -$3.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$15.6 million, a 186.97% decrease, with the full-year FY2024 number at -$17.4 million, down 197.3% from a year prior.
  • EBITDA was -$3.4 million for Q4 2024 at Palvella Therapeutics, up from -$5.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $38.0 million in Q4 2023 to a low of -$16.2 million in Q3 2021.
  • A 5-year average of -$5.6 million and a median of -$7.0 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 2305.67% in 2020, then skyrocketed 527.47% in 2023.
  • Palvella Therapeutics' EBITDA stood at -$13.9 million in 2020, then surged by 33.02% to -$9.3 million in 2021, then increased by 4.71% to -$8.9 million in 2022, then surged by 527.47% to $38.0 million in 2023, then tumbled by 108.87% to -$3.4 million in 2024.
  • Per Business Quant, the three most recent readings for PVLA's EBITDA are -$3.4 million (Q4 2024), -$5.1 million (Q3 2024), and -$4.4 million (Q2 2024).